Your browser is no longer supported. Please, upgrade your browser.
4D Molecular Therapeutics, Inc.
Index- P/E4.95 EPS (ttm)3.03 Insider Own2.80% Shs Outstand27.02M Perf Week-11.71%
Market Cap503.70M Forward P/E- EPS next Y-3.48 Insider Trans-9.51% Shs Float20.97M Perf Month-29.68%
Income-66.80M PEG0.14 EPS next Q-0.86 Inst Own69.50% Short Float6.66% Perf Quarter-53.69%
Sales17.00M P/S29.63 EPS this Y77.30% Inst Trans9.05% Short Ratio4.30 Perf Half Y-37.91%
Book/sh8.29 P/B1.81 EPS next Y-45.50% ROA- Target Price45.25 Perf Year-68.09%
Cash/sh4.82 P/C3.12 EPS next 5Y34.30% ROE- 52W Range14.25 - 55.11 Perf YTD-31.63%
Dividend- P/FCF- EPS past 5Y- ROI-22.10% 52W High-72.78% Beta-
Dividend %- Quick Ratio14.60 Sales past 5Y- Gross Margin- 52W Low5.26% ATR1.41
Employees121 Current Ratio14.60 Sales Q/Q-90.40% Oper. Margin- RSI (14)31.60 Volatility9.08% 7.60%
OptionableYes Debt/Eq0.00 EPS Q/Q88.00% Profit Margin- Rel Volume1.09 Prev Close14.28
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume325.14K Price15.00
Recom2.00 SMA20-21.10% SMA50-28.84% SMA200-44.10% Volume355,142 Change5.04%
Jan-04-22Initiated SVB Leerink Outperform $30
Jan-05-21Initiated Goldman Neutral $44
Jan-05-21Initiated Evercore ISI Outperform $70
Jan-05-21Initiated BofA Securities Buy $47
Jan-18-22 10:11AM  
Jan-10-22 08:02AM  
Jan-06-22 04:03PM  
Nov-29-21 04:00PM  
Nov-25-21 05:52AM  
Nov-23-21 04:05PM  
Nov-15-21 06:01AM  
Nov-10-21 04:01PM  
Oct-28-21 09:06PM  
Oct-26-21 05:52PM  
Oct-25-21 04:03PM  
Oct-10-21 03:50PM  
Oct-07-21 11:22AM  
Oct-06-21 08:27AM  
Sep-29-21 04:01PM  
Sep-24-21 07:03AM  
Aug-27-21 09:56AM  
Aug-12-21 04:04PM  
Jul-26-21 07:50PM  
Jun-28-21 09:38AM  
Jun-24-21 07:01AM  
Jun-07-21 07:00AM  
Jun-03-21 07:00AM  
May-13-21 04:03PM  
May-12-21 05:30PM  
May-10-21 04:35AM  
May-04-21 04:02PM  
Apr-30-21 07:05AM  
Apr-27-21 04:31PM  
Apr-26-21 10:16AM  
Apr-20-21 08:45AM  
Mar-25-21 04:02PM  
Mar-11-21 01:27AM  
Mar-09-21 08:03AM  
Dec-16-20 04:52PM  
Dec-15-20 04:05PM  
Dec-11-20 05:39PM  
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCHAFFER DAVIDDirectorOct 22Sale31.001,90058,893901,215Oct 22 09:42 PM
SCHAFFER DAVIDDirectorOct 21Sale31.5622,820720,156903,115Oct 22 09:42 PM
SCHAFFER DAVIDDirectorOct 20Sale31.0211,565358,771925,935Oct 22 09:42 PM
SCHAFFER DAVIDDirectorSep 30Sale26.9112,385333,250937,500Oct 01 04:34 PM
SCHAFFER DAVIDDirectorSep 29Sale28.6116,871482,614949,885Oct 01 04:34 PM
SCHAFFER DAVIDDirectorSep 28Sale30.5313,912424,693966,756Sep 29 04:05 PM
SCHAFFER DAVIDDirectorSep 27Sale32.8919,332635,826980,668Sep 29 04:05 PM
Moretti August JChief Financial OfficerApr 12Option Exercise9.411,0009,4102,000Apr 14 04:32 PM